Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven F Moss

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
Expert Opinion on Therapeutic Targets|May 17, 2007
Targeting Helicobacter pylori in gastric carcinogenesisDong Soo Lee, Steven F Moss
Alimentary Pharmacology & Therapeutics|July 18, 2019
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatmentErick A Argueta, Steven F Moss
Journal of Leukocyte Biology|May 15, 2014
At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancerRahul S Dalal, Steven F Moss
Journal of Clinical Gastroenterology|March 28, 2008
Symptom evaluation in gastroesophageal reflux diseaseIrvin M Modlin, Steven F Moss
Methods in Enzymology|December 12, 2002
Helicobacter pylori and apoptosisEmilia Mia Sordillo, Steven F Moss
Digestion|March 8, 2007
COX-2 inhibition and the prevention of gastric cancerDong-Soo Lee, Steven F Moss
The American Journal of Gastroenterology|January 26, 2022
Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, WhyDavid Y Graham, Steven F Moss
Current Opinion in Gastroenterology|August 19, 2021
The prevention of gastric cancer by Helicobacter pylori eradicationErick A Argueta, Steven F Moss
Human Vaccines|November 4, 2011
H. pylori vaccines: why we still don't have anySonghua Zhang, Leonard Moise, Steven F Moss
Basic & Clinical Pharmacology & Toxicology|June 14, 2025
High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?Neha Wadhavkar, Laura Varnum, Steven F Moss
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
Expert Opinion on Therapeutic Targets|May 17, 2007
Targeting Helicobacter pylori in gastric carcinogenesisDong Soo Lee, Steven F Moss
Alimentary Pharmacology & Therapeutics|July 18, 2019
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatmentErick A Argueta, Steven F Moss
Journal of Leukocyte Biology|May 15, 2014
At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancerRahul S Dalal, Steven F Moss
Journal of Clinical Gastroenterology|March 28, 2008
Symptom evaluation in gastroesophageal reflux diseaseIrvin M Modlin, Steven F Moss
Methods in Enzymology|December 12, 2002
Helicobacter pylori and apoptosisEmilia Mia Sordillo, Steven F Moss
Digestion|March 8, 2007
COX-2 inhibition and the prevention of gastric cancerDong-Soo Lee, Steven F Moss
The American Journal of Gastroenterology|January 26, 2022
Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, WhyDavid Y Graham, Steven F Moss
Current Opinion in Gastroenterology|August 19, 2021
The prevention of gastric cancer by Helicobacter pylori eradicationErick A Argueta, Steven F Moss
Human Vaccines|November 4, 2011
H. pylori vaccines: why we still don't have anySonghua Zhang, Leonard Moise, Steven F Moss
Basic & Clinical Pharmacology & Toxicology|June 14, 2025
High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?Neha Wadhavkar, Laura Varnum, Steven F Moss
Pageof 12